Special Issue

Metabolomics in Disease Mechanisms and Drug Targets

Message from the Guest Editor

Metabolomics, a distinct and comprehensive top-down methodology, offers profound insights into intricate systems. Through quantitative profiling of the metabolome, we can glean mechanistic insights into a myriad of biological functions and processes. Furthermore, metabolomics can illuminate potential new targets for the rapeutic intervention by pinpointing pathological metabolic shifts. The successful clinical development of therapies targeting these novel entities has heightened interest and appreciation of the value of metabolomics as a strategy for drug target identification. However, numerous challenges remain to be addressed, including understanding the connectivity and interactions among metabolites, elucidating complex disease mechanisms, and pinpointing appropriate drug targets. In light of these considerations, we invite original research articles and comprehensive reviews that illuminate the role of metabolomics in disease mechanism elucidation and drug target discovery, with a particular focus on innovative strategies and methodologies to overcome existing challenges.


Guest Editor

Dr. Kefeng Li

Faculty of Applied Sciences, Macao Polytechnic University, Macau SAR 999074, China

Deadline for manuscript submissions

closed (28 February 2025)



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/180600

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/ metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

